BBIO vs CCI · rev $221.9M vs P/E 40, rev $6.57B
BridgeBio Pharma Inc (BBIO) versus Crown Castle (CCI) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Crown Castle (CCI) is a reit - specialty company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported CCI revenue for 2024-12-31 was $6.57B. Net income was -$3.90B. Revenue was down 5.9% from 2023-12-31 to 2024-12-31. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
BBIO currently screens at market cap $13.24B. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
Not investment advice. Open the BBIO and CCI stock pages for the full models.
Not investment advice.